Markets
Luke Kawa
4/23/25

US stocks end higher even as euphoria over potential tariff relief fades

US stocks opened sharply higher after President Trump softened his stance on his two most market-unfriendly policies after the close on Tuesday: onerous tariffs on China and his desire to sack Fed Chair Jerome Powell.

However, major indexes finished well off their highs of the day after Treasury Secretary Scott Bessent said that any relief on China would not be unilateral. The S&P 500 ended 1.7% higher, the Nasdaq 100 advanced 2.3%, and the Russell 2000 went up 1.5%.

Consumer discretionary and tech were the top-performing S&P 500 sector ETFs, while energy and consumer staples finished lower. Oil stocks in particular were bedeviled by reports that OPEC+ is poised to boost production even more next month, while the softness in consumer staples was a story of traders ditching the safer stocks that have held up well during the market tumult in favor of riskier stocks.

Tesla was among the major drivers of gains in the S&P 500 today despite reporting underwhelming earnings on Tuesday after the close, thanks to CEO Elon Musk’s pledge to spend less time with DOGE and more with the company. Other so-called Trump trades like Palantir, Trump Media & Technology Group, and Axon also outperformed.

Potential relief on tariffs with China was positive for semi companies, with Intel one of the standouts in the industry amid reports that management is poised to cut 20% of its workforce.

Retailers were also massive beneficiaries of the less combative tone on cross-border commerce, with the likes of Victoria’s Secret and Five Below, which source products from Asia, outperforming the market.

Boeing’s turnaround plan continues to bear fruit, with the company’s first quarter of revenue growth since 2023 and a much smaller-than-expected loss per share driving upside for the stock.

Philip Morris gained after reporting better-than-expected earnings, buoyed by sales of enough Zyn cans to span Route 66.

Analysts at Bernstein have taken a shining to Mediterranean chain Cava, upgrading the stock and boosting their price target, contributing to a solid advance for the shares.

AT&T pared its big premarket gains on the heels of a ho-hum quarterly report in which earnings per share were in line with estimates.

CoreWeave put in another huge advance after Mike Novogratz’s Galaxy Digital deepened its partnership with the cloud-computing company at its data center campus.

More Markets

See all Markets
markets
Luke Kawa
24h

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

Nia Warfield, Luke Kawa
9/5/25
S&P 500 falls as rate-cut optimism fizzles

The S&P 500 gave up early gains to close down 0.3%, while the Nasdaq 100 eked out a 0.1% advance and the Russell 2000 outperformed, rising 0.5%.

Brown bear on a rock
markets
Nia Warfield
9/5/25

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

RFK Jr., HHS to Link Autism to Tylenol Use in Pregnancy and Folate Deficiencies

RFK Jr.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets
Max Knoblauch
9/5/25

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Matt Phillips
9/5/25
Palantir slips under 50-day moving average, amid momo reversal

What goes up, doesn’t always keep going up.

Palantir CEO Alex Karp PLTR insane valuation

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2025 Sherwood Media, LLC